<DOC>
	<DOCNO>NCT02559154</DOCNO>
	<brief_summary>To investigate efficacy modify bortezomib base combination therapy patient multiple myeloma .</brief_summary>
	<brief_title>Modified Bortezomib-based Combination Therapy Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma ( MM ) common hematological malignancy Chinese elderly population . The application novel drug improve clinical outcome survival MM patient , even though MM remain incurable hematological malignancy . Bortezomib typical one among novel agent , application result great success , adverse event high expense restrict widely usage . Investigators modify dose frequency bortezomib administration combination therapy : Patients modify group receive regimen bortezomib ( 1.6mg/㎡ ) intravenous bolus weekly day 1 , 8 3 week cycle , combination dexamethasone , without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide，while patient control group receive similar combination therapy except conventional bortezomib ( 1.3mg/㎡ ) administration twice weekly day 1,4 , 8,11 . The aim study investigate whether modify bortezomib-based therapy may attain similar efficacy conventional one .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis multiple myeloma base standard diagnosis criterion : plasmacytoma tissue biopsy bone marrow plasmacytosis monoclonal immunoglobulin spike serum electrophoresis lytic bone lesion . Must relapse relapsed/refractory disease 18 year age old All baseline study must perform within 21 day enrollment . ECOG performance status 0 2 Renal insufficiency ( serum creatinine level &gt; 2mg/dL ) Concomitant therapy medication include corticosteroid Peripheral neuropathy Grade 3 great painful Grade 2 Evidence mucosal internal bleeding and/or platelet refractory ANC &lt; 1000 cells/mm3 Hemoglobin &lt; 8.0 g/dL AST ( SGOT ALT ) &gt; 2 x ULN Intolerance bortezomib CC5013 past significant allergy either compound , boron mannitol Known hypersensitivity thalidomide development erythema nodosum Active infection serious comorbid medical condition Pregnant breastfeeding woman Prior malignancy last three year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , insitu prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>